HALIX facility approved for AstraZeneca’s COVID-19 vaccine active substance manufacturing

On Friday, March 26th 2021, HALIX’s facility has been approved by the European Medicines Agency (“EMA”) for the drug substance production of AstraZeneca’s COVID-19 vaccine, AZD 1222.

Link to the EMA announcement

About HALIX

HALIX B.V. is a biopharmaceutical contract development and manufacturing organization (CDMO) for biologics enabling the treatment and prevention of life threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substance and drug product. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX belongs to the family owned Droege Group AG. More information is available on:  www.halix.nl

Contact

Corporate Communications HALIX B.V.
Email: communications@halix.nl